The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Genomic instability in advanced non-small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIR02-Lung/ IFCT1301 trial.
 
Filippo Gustavo Dall'Olio
No Relationships to Disclose
 
Wael Zrafi
No Relationships to Disclose
 
Aaron Mamann
No Relationships to Disclose
 
Bastien Job
No Relationships to Disclose
 
Stefan Michiels
Consulting or Advisory Role - Biophytis; IQvia; Kedrion Biopharma; Roche; SERVIER; Yuhan
 
Pascale Tomasini
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol Myers Squibb Foundation; Janssen; Roche; Takeda
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb/Pfizer; Takeda
 
Judith Raimbourg
No Relationships to Disclose
 
Catherine Daniel
No Relationships to Disclose
 
Henri Janicot
No Relationships to Disclose
 
Anne Madroszyk
Honoraria - Janssen Oncology; Takeda
Consulting or Advisory Role - Janssen Oncology; Takeda
Travel, Accommodations, Expenses - BMS GmbH & Co. KG; Pfizer; Pfizer
 
Clarisse Audigier Valette
Consulting or Advisory Role - Abbvie; AstraZeneca; BMS GmbH & Co. KG; Janssen Oncology; Lilly; MSD Oncology; Pfizer; Roche; Sanofi; Takeda
Travel, Accommodations, Expenses - MSD Oncology; Pfizer
 
Ivan Bieche
No Relationships to Disclose
 
Julien Mazieres
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb; Hengrui Therapeutics; Lilly/ImClone; MSD; Novartis; Pfizer; Pierre Fabre; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Pierre Fabre (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer; Roche
 
Denis Lucien MORO SIBILOT
Consulting or Advisory Role - Abbvie; Amgen; ARIAD; AstraZeneca; Becton Dickinson; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Lilly/ImClone; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sanofi; Takeda
Research Funding - Abbvie (Inst); Boehringer Ingelheim France (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
Expert Testimony - MSD Oncology
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly/ImClone; MSD Oncology; Pfizer; Roche/Genentech
 
Marta Jimenez
No Relationships to Disclose
 
Virginie Westeel
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Roche
Consulting or Advisory Role - Ipsen
Speakers' Bureau - Amgen; Bristol-Myers Squibb/Pfizer; Lilly; MSD
Travel, Accommodations, Expenses - AstraZeneca; Bristol Myers Squibb; Roche; Sanofi
 
Alicia Tran-Dien
No Relationships to Disclose
 
Fabrice Barlesi
Consulting or Advisory Role - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai Europe (Inst); Lilly (Inst); Merck Serono (Inst); Mirati Therapeutics (Inst); MSD Oncology (Inst); Novartis (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst)
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Innate Pharma (Inst); Innate Pharma (Inst); Ipsen (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Benjamin Besse
Honoraria - Abbvie (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Hedera Dx (Inst); Janssen (Inst); MSD (Inst); Roche (Inst); Sanofi/Aventis (Inst); Springer Healthcare Ltd (Inst)
Consulting or Advisory Role - Abbvie (Inst); BioNTech SE (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); CureVac (Inst); Da voltera (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); F. Hoffmann LaRoche (Inst); Genmab (Inst); Immunocore (Inst); Janssen (Inst); Lilly (Inst); MSD Oncology (Inst); OSE Immunotherapeutics (Inst); Owkin (Inst); PharmaMar (Inst); Regeneron (Inst); Sanofi/Aventis (Inst); Taiho Oncology (Inst); Turning Point Therapeutics (Inst)
Research Funding - Abbvie (Inst); Amgen (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); BeiGene (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Enliven Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); Nuvalent, Inc. (Inst); OSE Immunotherapeutics (Inst); PharmaMar (Inst); Prelude Therapeutics (Inst); Roche/Genentech (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)